This post was originally published on this site

Globe Newswire

Global Aptamers Market to Reach $1.4 Billion by 2027

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 9. – Influencer Pool: 3393. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, March 30, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Antivenoms Industry” – https://www.reportlinker.com/p06039969/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. – Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: – Global Antivenoms Market to Reach $214.6 Million by 2027 – Amid the COVID-19 crisis, the global market for Antivenoms estimated at US$159.9 Million in the year 2020, is projected to reach a revised size of US$214.6 Million by 2027, growing at a CAGR of 4.3% over the analysis period 2020-2027. Snakes, one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$152.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Scorpion segment is readjusted to a revised 4.1% CAGR for the next 7-year period. – The U.S. Market is Estimated at $43.2 Million, While China is Forecast to Grow at 7% CAGR – The Antivenoms market in the U.S. is estimated at US$43.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$44.1 Million by the year 2027 trailing a CAGR of 6.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR. – Spiders Segment to Record 3.9% CAGR – In the global Spiders segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$13.2 Million in the year 2020 will reach a projected size of US$17 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$28.5 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period. – Select Competitors (Total 46 Featured) – Boehringer Ingelheim International GmbHBTG PLCCSL Ltd.Merck & Co., Inc.MicroPharm Ltd.Pfizer, Inc. Read the full report: https://www.reportlinker.com/p06039969/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Snakes by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Snakes by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Snakes by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Scorpion by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Scorpion by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Scorpion by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Spiders by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Spiders by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Spiders by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Other Animals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Other Animals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Other Animals by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Polyvalent Heterologous Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Polyvalent Heterologous Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Polyvalent Heterologous Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Monovalent Heterologous Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Monovalent Heterologous Antivenoms by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Monovalent Heterologous Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 22: USA Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 25: USA Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 CANADA Table 28: Canada Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 31: Canada Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 JAPAN Table 34: Japan Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 37: Japan Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 CHINA Table 40: China Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 43: China Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 EUROPE Table 46: Europe Current & Future Analysis for Antivenoms by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Antivenoms by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 49: Europe Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 FRANCE Table 55: France Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 58: France Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 GERMANY Table 61: Germany Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 64: Germany Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 ITALY Table 67: Italy Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 70: Italy Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 73: UK Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 76: UK Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 SPAIN Table 79: Spain Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 82: Spain Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 RUSSIA Table 85: Russia Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 88: Russia Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 REST OF EUROPE Table 91: Rest of Europe Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 94: Rest of Europe Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 97: Asia-Pacific Current & Future Analysis for Antivenoms by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Antivenoms by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 100: Asia-Pacific Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 AUSTRALIA Table 106: Australia Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 108: Australia 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 109: Australia Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 INDIA Table 112: India Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 113: India Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 114: India 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 115: India Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 SOUTH KOREA Table 118: South Korea Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 119: South Korea Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 120: South Korea 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 121: South Korea Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 123: South Korea 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 124: Rest of Asia-Pacific Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 125: Rest of Asia-Pacific Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 126: Rest of Asia-Pacific 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 127: Rest of Asia-Pacific Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 128: Rest of Asia-Pacific Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 129: Rest of Asia-Pacific 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 LATIN AMERICA Table 130: Latin America Current & Future Analysis for Antivenoms by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 131: Latin America Historic Review for Antivenoms by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 132: Latin America 15-Year Perspective for Antivenoms by Geographic Region – Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 Table 133: Latin America Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 134: Latin America Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 135: Latin America 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 136: Latin America Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 137: Latin America Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 138: Latin America 15-Year Perspective for Antivenoms by Type – Percentage Breakdown of Value Sales for Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms for the Years 2012, 2020 & 2027 ARGENTINA Table 139: Argentina Current & Future Analysis for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 140: Argentina Historic Review for Antivenoms by Animals – Snakes, Scorpion, Spiders and Other Animals Markets – Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 141: Argentina 15-Year Perspective for Antivenoms by Animals – Percentage Breakdown of Value Sales for Snakes, Scorpion, Spiders and Other Animals for the Years 2012, 2020 & 2027 Table 142: Argentina Current & Future Analysis for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Antivenoms – Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 143: Argentina Historic Review for Antivenoms by Type – Polyvalent Heterologous Antivenoms and Monovalent Heterologous Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06039969/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001